Longevity Peptide Dosage Protocols
Longevity research peptides target telomerase, senescent cell clearance, and pineal regulation. Epitalon, FOXO4-DRI, Vilon, Livagen, and NAD precursors are commonly studied.
8 protocols indexed
Vilon
Vilon is a synthetic dipeptide (Lys-Glu, KE) developed by Khavinson and colleagues as one of the shortest active peptide bioregulators, derived by directed synthesis from the amino acid composition of Thymalin, a bovine thymic extract used in Russian clinical immunology since the 1970s [1][2]. As a peptide of just two residues, Vilon represents the minimal active sequence in the Khavinson cytogen library and is investigated for thymic restoration, immune rejuvenation, and lifespan extension. In CBA mice receiving chronic Vilon administration starting at 6 months of age, Anisimov and Khavinson reported lifespan extensions of 20–40% with reduced spontaneous tumor incidence and improved immune markers [3]. Vilon is hypothesized to bind DNA directly through electrostatic complementarity of its Lys-Glu zwitterion to specific promoter sequences, modulating chromatin condensation and tissue-specific gene expression. Research dosing varies: 1–10 mcg/kg subcutaneously in animals, 100–500 mcg/day subcutaneously in research-community human use, or 1–10 mg/day orally in Russian bioregulator practice. Vilon is registered in Russia under bioregulator legislation but has no FDA, EMA, or MHRA approval.
Open Protocolarrow_forwardResearch PeptideVesugen
Vesugen is a synthetic tripeptide (Lys-Glu-Asp, KED) developed by Vladimir Khavinson and colleagues as a tissue-specific bioregulator targeting the vascular endothelium and broader cardiovascular system [1][2]. It is one of the Khavinson cytogen family, derived from analysis of the amino acid composition of vascular wall protein extracts and synthesized as a defined short-peptide bioregulator for endothelial gene-program modulation. Preclinical work documents binding to the MKI67 gene promoter and modulation of endothelin-1 (EDN1), connexin (GJA1/Cx43), and SIRT1 expression in vascular cells, supporting effects on endothelial proliferation, intercellular communication, and longevity-associated gene programs [3]. Research dosing is 100–500 mcg subcutaneously per day across 10–20 day cycles, or 1–10 mg/day orally in outpatient Russian bioregulator practice, repeated 2–4 times yearly. Vesugen is registered in Russia under peptide-bioregulator and dietary-supplement legislation but has no FDA, EMA, or MHRA approval. Human clinical evidence is limited to Russian observational use in age-related vascular disorders.
Open Protocolarrow_forwardBioregulator PeptideCartalax
Cartalax is a synthetic tripeptide (Ala-Glu-Asp, AED) developed by Vladimir Khavinson and colleagues as a tissue-specific bioregulator targeting cartilage, chondrocytes, and musculoskeletal connective tissue [1][2]. Derived by directed synthesis from analysis of cartilage protein composition, Cartalax shares the AED motif with several other Khavinson peptides but is positioned within the cytogen library as cartilage-targeted on the basis of its preferential effects in chondrocyte cultures and fibroblast-derived musculoskeletal cell lines [3]. Preclinical work shows Cartalax reduces aging markers p16, p21, and p53 while increasing SIRT6, a longevity-associated histone deacetylase, in cartilage cultures. The peptide also activates extracellular matrix gene programs and reduces chondrocyte apoptosis under metabolic stress. Research dosing is 100–500 mcg subcutaneously per day across 10–20 day cycles, or 1–10 mg/day orally in outpatient Russian bioregulator practice. Cartalax is registered in Russia under peptide-bioregulator and dietary-supplement legislation but has no FDA, EMA, or MHRA approval. Human clinical evidence is limited to observational reports in age-related joint and connective-tissue disorders.
Open Protocolarrow_forwardBioregulator PeptideEpitalon
Epitalon (also Epithalon, Epithalamin tetrapeptide) is a synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG) developed by Vladimir Khavinson by directed synthesis from the amino-acid composition of bovine pineal extract Epithalamin [1][2]. It is the most extensively studied of the Khavinson peptide bioregulators, with documented effects on telomerase activation, telomere elongation, melatonin restoration, and lifespan extension in rodent and Drosophila models [3][4][5]. Khavinson and colleagues showed Epitalon activates telomerase in human fetal somatic cell cultures with observable telomere elongation, and Anisimov demonstrated 12–13% lifespan extension in mice and 11–16% in fruit flies [6]. Standard research dosing is 5–10 mg subcutaneously per day for 10–20 consecutive days, repeated 2–3 times yearly. Epitalon is registered as a peptide bioregulator in Russia but is not approved by the FDA, EMA, or MHRA; outside Russia it is a research-only compound. Human clinical evidence is limited to Russian observational use in age-related disorders, with reports of restored circadian melatonin rhythms, improved immune markers, and normalized neuroendocrine function.
Open Protocolarrow_forwardResearch PeptideFOXO4-DRI
FOXO4-DRI is a 43-amino-acid synthetic senolytic peptide developed by Peter de Keizer and colleagues, first described in the landmark Cell 2017 paper as the first peptide-based agent to selectively eliminate senescent cells in mice through targeted disruption of the FOXO4-p53 interaction [1]. The 'DRI' designation reflects its D-retro-inverso engineering: all amino acids are replaced with their D-isomers and the sequence is reversed, producing a peptide highly resistant to enzymatic degradation while preserving target binding [2]. In senescent cells, FOXO4 sequesters p53 in the nucleus and blocks apoptosis; FOXO4-DRI competitively displaces FOXO4 from p53, releasing p53 to trigger intrinsic apoptosis selectively in senescent cells while sparing healthy cells [1][3]. In aged mice, intraperitoneal FOXO4-DRI restored fur density, renal function, and physical fitness. FOXO4-DRI has no human clinical trial data, no FDA or EMA approval, and is sold strictly as a research chemical. Mouse-equivalent doses are 5 mg/kg three times weekly; safe and effective human dosing is unknown.
Open Protocolarrow_forwardBioregulator PeptideLivagen
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, KEDA) developed by Vladimir Khavinson and colleagues as a tissue-specific bioregulator targeting hepatic tissue and immune function [1][2]. Synthesized by directed analysis of liver and immune-organ peptide preparations, Livagen is one of the better-characterized Khavinson cytogens with documented effects on heterochromatin decondensation in hepatocyte nuclei — a structural manifestation of the broader bioregulator hypothesis that short peptides remodel chromatin to reactivate age-silenced gene programs [3]. Preclinical work shows Livagen normalizes hepatocyte function in aged rats, restores age-impaired protein synthesis programs, and modulates immune gene expression in lymphocytes. Research dosing is 100–500 mcg subcutaneously per day across 10–20 day cycles, or 1–10 mg/day orally in outpatient Russian bioregulator practice, repeated 2–4 times per year. Livagen is registered in Russia under peptide-bioregulator and dietary-supplement legislation but has no FDA, EMA, or MHRA approval. Human clinical evidence is limited to observational use in age-related hepatic and immune disorders.
Open Protocolarrow_forwardLongevity & Metabolic SupportNAD
NAD+ (nicotinamide adenine dinucleotide) is the central redox and signaling cofactor for hundreds of enzymes including sirtuins (SIRT1–7), poly(ADP-ribose) polymerases (PARPs), and CD38, with intracellular concentrations declining substantially with age across human tissues [1][2]. Sinclair, Imai, and colleagues established sirtuins as NAD-dependent deacetylases that regulate longevity, metabolism, and DNA repair, and showed that restoring NAD+ levels through precursor supplementation can reverse age-related metabolic decline in mice [3][4]. Yoshino and colleagues demonstrated in a randomized clinical trial that nicotinamide mononucleotide (NMN) at 250 mg/day improves muscle insulin sensitivity in prediabetic women [5]. NAD+ itself is administered as a research and integrative medicine intervention at 100–500 mg subcutaneously or intramuscularly, or 250–1000 mg by slow intravenous infusion over 1–4 hours, in cycles. NAD+ is sold as a supplement (oral, sublingual, injectable) but the FDA has not approved NAD+ injection for any therapeutic indication. NAD+ precursors (NR, NMN) have FDA NDI status as dietary supplements but are not approved drugs.
Open Protocolarrow_forwardTherapeutic BlendKLOW
KLOW is a research-chemical blend of four regenerative peptides — typically 50 mg GHK-Cu (copper tripeptide), 10 mg KPV (alpha-MSH C-terminal tripeptide), 10 mg BPC-157 (body protection compound), and 10 mg TB-500 (thymosin beta-4 C-terminal fragment) — combined in a single 80 mg lyophilized vial for parenteral reconstitution. The blend is not a single registered compound but a research-community formulation designed to deliver complementary tissue-repair, anti-inflammatory, angiogenic, and matrix-remodeling activities in one injection. GHK-Cu stimulates collagen synthesis and angiogenesis (Pickart) [1]; KPV is the C-terminal anti-inflammatory tripeptide of alpha-MSH (Lipton, Catania) [2]; BPC-157 is a 15-amino-acid gastric peptide derivative with documented soft-tissue healing activity in animal models (Sikiric) [3][4]; TB-500 is a synthetic fragment of thymosin beta-4 supporting actin remodeling, cell migration, and angiogenesis [5]. None of these peptides are FDA approved as drugs; KLOW is sold strictly as a research chemical. Typical research dosing is 500–1000 mcg blend subcutaneously per day in 4–6 week cycles.
Open Protocolarrow_forward